Sees FY23 revenue view $5.6B-$6B, consensus $5.71B. Projecting 2023 TAVR sales of $3.6 – $4.0 billion; underlying growth of 9% – 12%. Projecting 2023 TMTT sales of $160 – $200 million. Focused long-term growth investments with 2023 R&D planned at 17% – 18% of sales. Meaningful progress on 8 pivotal trials across TAVR and TMTT.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EW:
- EDWARDS LIFESCIENCES OUTLINES GROWTH STRATEGY AT ANNUAL INVESTOR CONFERENCE
- Edwards Lifesciences to host investor meeting
- Edwards Lifesciences price target lowered to $85 from $100 at Mizuho
- Edwards Lifesciences downgraded to Hold from Buy at Stifel
- Edwards Lifesciences call volume above normal and directionally bullish
